{"id":"vehicle-cream","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vehicle Cream serves as a pharmaceutical excipient and delivery platform rather than an active drug itself. It is designed to provide an appropriate medium for topical application, ensuring proper absorption, stability, and patient tolerability of active ingredients when incorporated into the formulation.","oneSentence":"Vehicle Cream is an inert topical formulation base used as a delivery system for active pharmaceutical ingredients in dermatological applications.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:15:04.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pharmaceutical vehicle/excipient for topical dermatological formulations"}]},"trialDetails":[{"nctId":"NCT03372811","phase":"PHASE2","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)","status":"COMPLETED","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2015-06-11","conditions":"Psoriasis Vulgaris, Topical Administration","enrollment":88},{"nctId":"NCT07482787","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","status":"NOT_YET_RECRUITING","sponsor":"Paradigm Therapeutics","startDate":"2026-05-15","conditions":"Epidermolysis Bullosa (EB)","enrollment":80},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT07013201","phase":"PHASE2","title":"A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2025-09-11","conditions":"Palmoplantar Pustulosis","enrollment":135},{"nctId":"NCT07265479","phase":"PHASE3","title":"A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis","status":"RECRUITING","sponsor":"Organon and Co","startDate":"2025-12-29","conditions":"Atopic Dermatitis","enrollment":180},{"nctId":"NCT06958211","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-12","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06959225","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-23","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06286397","phase":"PHASE2","title":"Topical Anti-Androgens in Pilonidal Sinus Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-01-10","conditions":"Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus","enrollment":75},{"nctId":"NCT07079969","phase":"PHASE2","title":"Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04","conditions":"Knee Pain Chronic","enrollment":32},{"nctId":"NCT07426120","phase":"PHASE3","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","status":"RECRUITING","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2026-02-01","conditions":"Psoriasis Vulgaris, Topical Administration, Phase III","enrollment":300},{"nctId":"NCT07335588","phase":"PHASE3","title":"A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus","status":"NOT_YET_RECRUITING","sponsor":"LEO Pharma","startDate":"2026-05-06","conditions":"Lichen Sclerosus","enrollment":652},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT03954236","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-05-14","conditions":"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease","enrollment":24},{"nctId":"NCT07357831","phase":"PHASE3","title":"A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-12-26","conditions":"Plaque Psoriasis","enrollment":537},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT07345390","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","startDate":"2026-01-10","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT07301515","phase":"NA","title":"Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin","status":"COMPLETED","sponsor":"Klira Skin","startDate":"2025-03-01","conditions":"Photoaging, Photodamage, Mitochondrial Damage","enrollment":52},{"nctId":"NCT04845620","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-04-07","conditions":"Atopic Dermatitis Eczema","enrollment":652},{"nctId":"NCT06832618","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-17","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT05764161","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-06-12","conditions":"Prurigo Nodularis","enrollment":190},{"nctId":"NCT06548360","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-24","conditions":"NonSegmental Vitiligo","enrollment":180},{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT06804811","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-11-13","conditions":"NonSegmental Vitiligo","enrollment":250},{"nctId":"NCT05190770","phase":"PHASE2","title":"A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-15","conditions":"Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I","enrollment":18},{"nctId":"NCT07259343","phase":"NA","title":"Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population","status":"RECRUITING","sponsor":"Universidad Autónoma de Aguascalientes","startDate":"2025-09-26","conditions":"Atopic Dermatitis (AD)","enrollment":20},{"nctId":"NCT07203274","phase":"NA","title":"The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch","status":"NOT_YET_RECRUITING","sponsor":"Aalborg University","startDate":"2025-12-01","conditions":"Itchiness","enrollment":30},{"nctId":"NCT07186413","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris","status":"RECRUITING","sponsor":"Galderma R&D","startDate":"2025-09-23","conditions":"Acne Vulgaris","enrollment":561},{"nctId":"NCT06807021","phase":"PHASE2, PHASE3","title":"Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients","status":"RECRUITING","sponsor":"Birch BioMed Inc","startDate":"2025-12-01","conditions":"Burn Scar, Burn Wound","enrollment":70},{"nctId":"NCT05755438","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-03-10","conditions":"Prurigo","enrollment":204},{"nctId":"NCT06238817","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-04-26","conditions":"Atopic Dermatitis","enrollment":241},{"nctId":"NCT06132919","phase":"PHASE2","title":"Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2023-10-11","conditions":"Vulvar Lichen Sclerosus","enrollment":33},{"nctId":"NCT06004050","phase":"PHASE3","title":"A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2023-09-05","conditions":"Chronic Hand Eczema","enrollment":362},{"nctId":"NCT05860881","phase":"PHASE3","title":"Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2024-02-09","conditions":"Solid Organ Transplant Recipients, Skin Cancer","enrollment":146},{"nctId":"NCT05014568","phase":"PHASE3","title":"Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2021-09-01","conditions":"Atopic Dermatitis","enrollment":407},{"nctId":"NCT05765487","phase":"PHASE1","title":"Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%","status":"COMPLETED","sponsor":"Daré Bioscience, Inc.","startDate":"2023-05-13","conditions":"Sexual Arousal Disorder","enrollment":13},{"nctId":"NCT06631170","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":"Atopic Dermatitis (AD)","enrollment":354},{"nctId":"NCT05032859","phase":"PHASE3","title":"Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2021-09-23","conditions":"Atopic Dermatitis","enrollment":406},{"nctId":"NCT06880276","phase":"PHASE3","title":"Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-05-16","conditions":"Atopic Dermatitis","enrollment":360},{"nctId":"NCT04057573","phase":"PHASE3","title":"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-10-03","conditions":"Non-segmental Vitiligo","enrollment":344},{"nctId":"NCT04052425","phase":"PHASE3","title":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-09-20","conditions":"Non-segmental Vitiligo","enrollment":330},{"nctId":"NCT04530344","phase":"PHASE3","title":"Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2020-09-24","conditions":"Vitiligo","enrollment":458},{"nctId":"NCT04896385","phase":"PHASE2","title":"A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-06-23","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT05906628","phase":"PHASE2","title":"Topical Ruxolitinib Evaluation in Chronic Hand Eczema","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-07-31","conditions":"Hand Eczema","enrollment":186},{"nctId":"NCT05355818","phase":"PHASE3","title":"Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2022-07-14","conditions":"Chronic Hand Eczema","enrollment":98},{"nctId":"NCT06403501","phase":"PHASE3","title":"Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris","status":"RECRUITING","sponsor":"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","startDate":"2024-05-20","conditions":"Acne Vulgaris","enrollment":692},{"nctId":"NCT06531512","phase":"PHASE2, PHASE3","title":"Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2024-08-16","conditions":"Diabetic Foot Ulcer","enrollment":120},{"nctId":"NCT03956355","phase":"PHASE3","title":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-21","conditions":"Plaque Psoriasis","enrollment":510},{"nctId":"NCT03983980","phase":"PHASE3","title":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-06-06","conditions":"Plaque Psoriasis","enrollment":515},{"nctId":"NCT06980961","phase":"NA","title":"Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis","status":"RECRUITING","sponsor":"Science Valley Research Institute","startDate":"2025-05-20","conditions":"Stasis Dermatitis","enrollment":20},{"nctId":"NCT05891795","phase":"PHASE1, PHASE2","title":"Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-07-22","conditions":"Acne Vulgaris","enrollment":18},{"nctId":"NCT06648772","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Plaque Psoriasis","enrollment":189},{"nctId":"NCT05279495","phase":"NA","title":"Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers","status":"COMPLETED","sponsor":"MINO Labs, LLC","startDate":"2023-01-15","conditions":"Photoaging","enrollment":20},{"nctId":"NCT04313400","phase":"PHASE1, PHASE2","title":"Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Amytrx Therapeutics, Inc.","startDate":"2020-03-10","conditions":"Atopic Dermatitis","enrollment":91},{"nctId":"NCT04872101","phase":"PHASE3","title":"Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2021-05-25","conditions":"Chronic Hand Eczema","enrollment":473},{"nctId":"NCT04871711","phase":"PHASE3","title":"Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2021-05-10","conditions":"Chronic Hand Eczema","enrollment":487},{"nctId":"NCT04921969","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-07-19","conditions":"Atopic Dermatitis","enrollment":330},{"nctId":"NCT05259774","phase":"NA","title":"Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric Patients","status":"COMPLETED","sponsor":"Relife S.r.l.","startDate":"2022-10-27","conditions":"Atopic Dermatitis","enrollment":60},{"nctId":"NCT05482698","phase":"PHASE2","title":"The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2022-07-01","conditions":"Chronic Kidney Disease-associated Pruritus","enrollment":111},{"nctId":"NCT04962139","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2021-07-27","conditions":"Chronic Diabetic Foot Ulcers","enrollment":12},{"nctId":"NCT06058000","phase":"PHASE2","title":"A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-11-13","conditions":"Atopic Dermatitis","enrollment":120},{"nctId":"NCT00875277","phase":"PHASE2","title":"A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT03683719","phase":"PHASE2","title":"Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-11-28","conditions":"Chronic Hand Eczema","enrollment":258},{"nctId":"NCT01580488","phase":"PHASE1","title":"A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT03725722","phase":"PHASE2","title":"Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-12-28","conditions":"Atopic Dermatitis","enrollment":251},{"nctId":"NCT01037881","phase":"PHASE2","title":"LEO 29102 Cream in the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-12","conditions":"Atopic Dermatitis","enrollment":183},{"nctId":"NCT00764751","phase":"PHASE2","title":"Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-09","conditions":"Psoriasis Vulgaris","enrollment":51},{"nctId":"NCT05332366","phase":"PHASE2","title":"A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2022-04-19","conditions":"Frontal Fibrosing Alopecia","enrollment":35},{"nctId":"NCT03958955","phase":"PHASE2","title":"Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2019-07-09","conditions":"Discoid Lupus Erythematosus","enrollment":27},{"nctId":"NCT00986856","phase":"PHASE4","title":"Fucidin® Cream in the Treatment of Impetigo","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2004-05","conditions":"Impetigo","enrollment":58},{"nctId":"NCT05579899","phase":"PHASE2","title":"Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis","status":"COMPLETED","sponsor":"Evommune, Inc.","startDate":"2022-09-27","conditions":"Atopic Dermatitis Eczema","enrollment":119},{"nctId":"NCT02376049","phase":"PHASE1","title":"A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT01722812","phase":"PHASE2","title":"Cromoglicate in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-11","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02103725","phase":"PHASE1","title":"A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT01850849","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-05","conditions":"Atopic Dermatitis","enrollment":23},{"nctId":"NCT04807751","phase":"PHASE1","title":"Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2021-03-25","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT04361136","phase":"PHASE1","title":"Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2020-04-23","conditions":"Healthy Volunteers","enrollment":35},{"nctId":"NCT00958516","phase":"PHASE1","title":"Assessment of the Phototoxic Potential of LEO 29102 Cream","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-09","conditions":"Atopic Dermatitis","enrollment":32},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":"Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT03395132","phase":"PHASE3","title":"Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2018-07-31","conditions":"Infected Atopic Dermatitis/Eczema","enrollment":68},{"nctId":"NCT02219633","phase":"PHASE1","title":"Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-07","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT01447758","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Atopic Dermatitis","enrollment":58},{"nctId":"NCT00891709","phase":"PHASE1","title":"LEO 29102 Single and Multiple Dose Study by Dermal Application","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-03","conditions":"Atopic Dermatitis","enrollment":64},{"nctId":"NCT06833996","phase":"NA","title":"The Efficacy of Bakuchiol in Treating PIH","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2016-02-22","conditions":"Post Inflammatory Hyperpigmentation","enrollment":22},{"nctId":"NCT02427724","phase":"EARLY_PHASE1","title":"The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2015-04","conditions":"Lentigo","enrollment":48},{"nctId":"NCT06245564","phase":"NA","title":"Effect of Ketamine, Amitriptyline and Their Combination on Itch","status":"COMPLETED","sponsor":"Aalborg University","startDate":"2024-08-20","conditions":"Itch","enrollment":30},{"nctId":"NCT04685577","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-07-10","conditions":"Burn; Multiple Body Regions, Max. Second Degree, Third-Degree Burn, Burn Degree Second","enrollment":60},{"nctId":"NCT06733402","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-06-20","conditions":"Acne Vulgaris","enrollment":1000},{"nctId":"NCT03308799","phase":"PHASE3","title":"A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2017-10-03","conditions":"Psoriasis Vulgaris","enrollment":794},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT06695143","phase":"PHASE3","title":"Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2025-04","conditions":"Leishmaniasis, Cutaneous","enrollment":180},{"nctId":"NCT03680131","phase":"PHASE2","title":"Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis","status":"COMPLETED","sponsor":"Edesa Biotech Inc.","startDate":"2019-10-15","conditions":"Allergic Contact Dermatitis","enrollment":211},{"nctId":"NCT05206604","phase":"PHASE1","title":"A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT06673654","phase":"PHASE1","title":"A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-08-11","conditions":"Atopic Dermatitis","enrollment":476},{"nctId":"NCT05635838","phase":"PHASE2","title":"Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-12-07","conditions":"Hidradenitis Suppurativa","enrollment":69},{"nctId":"NCT05593432","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-11-23","conditions":"Cutaneous Lichen Planus","enrollment":64},{"nctId":"NCT04773587","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-01-27","conditions":"Atopic Dermatitis Eczema","enrollment":654},{"nctId":"NCT04773600","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-24","conditions":"Atopic Dermatitis Eczema","enrollment":683},{"nctId":"NCT05550337","phase":"PHASE3","title":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2022-09-19","conditions":"Acne Vulgaris","enrollment":807},{"nctId":"NCT05593445","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-11-18","conditions":"Lichen Sclerosus","enrollment":61},{"nctId":"NCT05127421","phase":"PHASE2","title":"Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-11-10","conditions":"Atopic Dermatitis","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":198,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo","Placeco","Vehicle","HSA","Human Serum Albumin"],"phase":"marketed","status":"active","brandName":"Vehicle Cream","genericName":"Vehicle Cream","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Cream is an inert topical formulation base used as a delivery system for active pharmaceutical ingredients in dermatological applications. Used for Pharmaceutical vehicle/excipient for topical dermatological formulations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":23,"withResults":16},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}